Adaptive Biotechnologies Corporation
Corporate Bias Rating
Expand Summary
Risk Level:
Summary:
Adaptive Biotechnologies Corporation often yields to political activism in shaping corporate governance, potentially alienating consumers, dividing employees, and harming shareholders. The company implements race and identity-based policies that replace merit, excellence, and integrity with preferential treatment and outcomes. Adaptive Biotechnologies Corporation occasionally embraces corporate initiatives that redirect its central focus from business goals to partisan policies and divisive issues at times. This approach fails to safeguard free exercise, free speech, and free enterprise.
View Full Corporate Bias Ratings ReportHas canceled customers, suppliers, or vendors due to their political views or religious beliefs OR corporately boycotts, divests, or sanctions regions, people groups, or industries.
Adaptive Biotechnologies received a score of 100 on the 2026 Corporate Equality Index (CEI) from the Human Rights Campaign (HRC), a political stakeholder group. The company recruits employees based on sexual identity issues. The company discriminates against vendors that do not promote divisive sex and gender policies, indicating it prioritizes sexual issues over merit(1)(2)(3). The company received a score of 80 on the 2025 Corporate Equality Index (CEI) from the Human Rights Campaign (HRC), a political stakeholder group. The company recruits employees based on sexual identity issues. The company discriminates against vendors that do not promote divisive sex and gender policies, indicating it prioritizes sexual issues over merit (4)(5). Adaptive Biotechnologies has not publicly canceled customers, suppliers, or vendors based on political views or religious beliefs (6).
Charitable giving (including employee matching programs) policies or practices discriminate against charitable organizations based on views or religious beliefs.
Adaptive Biotechnologies Corporation’s HRC 2026 CEI rating indicates the company will not donate to non-religious charities unless they embrace controversial sexual identity policies (1)(2)(3). Adaptive Biotechnologies Corporation’s HRC 2025 CEI rating indicates the company will not donate to non-religious charities unless they embrace controversial sexual identity policies (4)(5). However, the company does not publish charitable giving guidelines (6).
Employment policies fail to protect against viewpoint or other discrimination and/or are ideological in nature.
Adaptive Biotechnologies Corporation’s HRC 2026 CEI rating indicates the company provides gender transition guidelines for its employees and a specific benefits guide with a comprehensive explanation of transgender services funded by the company (1)(2)(3). Adaptive Biotechnologies Corporation’s HRC 2025 CEI rating indicates the company provides gender transition guidelines for its employees and a specific benefits guide with a comprehensive explanation of transgender services funded by the company (4)(5). However, Adaptive Biotechnologies does not publish a nondiscrimination policy (6).
Uses corporate reputation to support causes, organizations, or policies hostile to freedom of expression.
Adaptive Biotechnologies Corporation HRC 2026 CEI rating indicates the company potentially agrees to allow a controversial stakeholder group focused on sexual identity issues to dictate marketing or advertising strategy. By doing so, the company risks dividing employees, alienating customers and harming shareholders (1)(2)(3). The company has not supported ideological causes or policies (4).
Uses corporate funds to advance ideological causes, organizations, or policies hostile to freedom of expression.
Adaptive Biotechnologies Corporation’s HRC 2026 CEI rating indicates the company has potentially pledged philanthropic support of at least one organization or event that promotes sex and gender ideology. By allowing a political stakeholder group to dictate operations, the company increases health care costs and risks dividing employees, alienating customers and harming shareholders (1)(2)(3). The company’s HRC 2025 CEI rating indicates the company covers transgender related costs for its employees and their children, including paid short-term leave, puberty blockers, cross-sex hormones, chest surgeries, genital surgeries, medical visits and lab monitoring, travel and lodging (4)(5). Otherwise, there are no publicly known cases of Adaptive Biotechnologies using corporate funds to advance ideological causes, organizations, or policies (6).
Board Bias
Expand Summary
1792 Exchange has not yet compiled data about the board of directors or political contributions of leadership for this company.